Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has approved secukinumab (Cosentyx, Novartis) for adults with polymyalgia rheumatica (PMR), making it the second biologic — and first anti-IL-17 therapy — cleared for the condition. The approval is based on the phase 3 REPLENISH trial, where secukinumab doubled sustained remission rates compared to placebo at one year. It's indicated for patients who haven't responded adequately to corticosteroids or can't tolerate steroid tapering.
The FDA has approved secukinumab (Cosentyx, Novartis), an interleukin-17 inhibitor, for the treatment of adults with polymyalgia rheumatica (PMR) — a chronic inflammatory condition that makes everyday tasks like getting dressed or lifting one's arms painfully difficult. This marks the second biologic approved for PMR, following sarilumab (Kevzara) in March 2023, and the first anti-IL-17 therapy for the disease. It's specifically indicated for patients with an inadequate response to corticosteroids or who cannot tolerate steroid tapering.
The approval is grounded in data from the phase 3 REPLENISH trial — a multicenter, randomized, double-blind, placebo-controlled study of 381 patients across 27 countries, published in the New England Journal of Medicine. The trial showed secukinumab significantly outperformed placebo in achieving sustained remission after a 24-week steroid taper.
By the Numbers:
Why it matters: For too long, PMR patients have been stuck relying on long-term steroids, which carry significant risks. Secukinumab's approval gives clinicians a new, targeted option to help patients achieve remission while reducing steroid dependence — a meaningful step forward in individualized PMR care.